Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, S. Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211'. Together they form a unique fingerprint.